Everything below concerns LC-MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
=== Chairmen === Chairman of the Anti-Fascist Council of People's Liberation of Bosnia and Herzegovina Vojislav Kecmanović (25 November 1943 – 26 April 1945) Chairmen of the Presidium of the People's Assembly Vojislav Kecmanović (26 April 1945 – November 1946) Đuro Pucar (November 1946 – September 1948) Vlado Šegrt (September 1948 – March 1953) Chairmen of the People's Assembly Đuro Pucar (December 1953 – June 1963) Ratomir Dugonjić (June 1963 – July 1967) Džemal Bijedić (1967 – July 1971) Hamdija Pozderac (July 1971 – May 1974) Chairmen of the Presidency Ratomir Dugonjić (May 1974 – April 1978) Raif Dizdarević (April 1978 – April 1982) Branko Mikulić (April 1982 – 26 April 1984) Milanko Renovica (26 April 1984 – 26 April 1985) Munir Mesihović (26 April 1985 – April 1987) Mato Andrić (April 1987 – April 1988) Nikola Filipović (April 1988 – April 1989) Obrad Piljak (April 1989 – 20 December 1990) Alija Izetbegović (20 December 1990 – 8 April 1992)
== Discovery == German chemist Felix Ehrlich discovered isoleucine while studying the composition of beet-sugar molasses 1903. In 1907 Ehrlich carried out further studies on fibrin, egg albumin, gluten, and beef muscle in 1907. These studies verified the natural composition of isoleucine. Ehrlich published his own synthesis of isoleucine in 1908.
He added, "It's an honor to be with you, it's an honor to be your friend", while saying he hoped the relationship would be "better than ever before". The two leaders then had talks behind closed doors following the opening remarks. The talks lasted two hours in total, double the duration originally scheduled. The two leaders exchanged views on the Iran war, the Russo-Ukrainian war, and the Korean Peninsula. The White House stated that the two sides had "discussed ways to enhance economic cooperation", including by US companies' access to the Chinese economy and Chinese investment in US industries. The statement also said they discussed the importance of ending the flow of fentanyl precursors into the US. Regarding the Iran war, the White House said "both countries agreed that Iran can never have a nuclear weapon" and that "the two sides agreed that the Strait of Hormuz must remain open to support the free flow of energy", while adding Xi had expressed opposition to the militarization of the Strait of Hormuz and efforts to charge a toll for its use and expressed interest in China buying oil from the US. The Financial Times later reported that, Xi had condemned Japanese prime minister Sanae Takaichi for Japan's "remilitarisation", with Xi reportedly becoming "vocal and agitated when discussing Japan". Adding that this was the most intense part of Trump's visit, the Financial Times reported Trump had responded by saying Japan had to take a more assertive defense stance due to rising threats from North Korea.
Sources: en.wikipedia.org
== Beginning of the war == On September 1, 1939, Hitler's Germany began its invasion of Poland, marking the beginning of World War II. On September 4, President Lázaro Cárdenas, faithful to Mexico's pacifist policy, declared neutrality in the European conflict, which was seen as a new kind of war. However, neutrality did not prevent the government from condemning aggression against the sovereignty of democratic nations. Mexico recognized the Polish government-in-exile, and in December 1939, it criticized the Soviet invasion of Finland. In 1940 and 1941, Mexico condemned the German invasions of Norway, the Netherlands, Belgium, Greece and Yugoslavia. Before the German aggression against Holland and Belgium, Cárdenas declared on May 13, 1940 that:
== Deployments == In Côte d'Ivoire the system has been implemented across a national network of clinical laboratories as part of an HIV and public-health laboratory data programme. In 2020, the United Nations Development Programme (UNDP) country office in Mauritius acted as liaison to implement OpenELIS at the country's Central Health Laboratory during the COVID-19 pandemic; UNDP reported that the deployment reduced the staff required to process and report test data and avoided a substantially larger procurement cost. Implementations have also been reported in Kenya.
which is about 28 microseconds. If there were a singly charged tryptic peptide ion with 4000 Da mass, and it is four times larger than the 1000 Da mass, it would take twice the time, or about 56 microseconds to traverse the flight tube, since time is proportional to the square root of the mass-to-charge ratio.
The study was double-blind and placebo-controlled. Patients had HCV GT1, GT4, or GT6 and were on opioid therapy. Upwards of 96% of the patients achieved SVR24. This study contributed to the knowledge of the incidence of HCV reinfection in patients who receive drug injection of opioid treatments. This is a demographic that the medical community is typically reluctant to treat due to concerns of reinfection and compliance.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.